Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LiTT Combined With Cemiplimab Versus Chemotherapy in Recurrent Glioblastoma
NCT07620548Phase 2Not yet recruiting
- Sponsor
- Washington University School of Medicine
- Start
- Nov 2026
- Primary completion
- May 2031
- Countries
- 1
01
Overview
A Phase 2 trial of cemiplimab in glioblastoma (GBM), sponsored by Washington University School of Medicine. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
cemiplimab
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT07620548.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07620548.